Peptide Drug Conjugates Market Report 2023: R&D Consistency Drives Sector Growth
The global market for Peptide Drug Conjugates is expected to be worth $861.12 million in 2023, rising to $5,331.83 million by 2033. The projected growth rate for the forecast period of 2023 to 2033 is nearly 20%. The global peptide drug conjugates market is expected to be worth $717.6 million by 2022, with a historical CAGR of 16%. Pharmaceutical companies are developing PDCs for a variety of diseases, including metabolic diseases, coronavirus diseases, and cancer. For cancer treatment, the market currently has two FDA-approved drugs: Pepaxto (Melflufen) and Lutathera (Lu 177 dotatate). As a result, the increasing prevalence of such diseases is propelling the peptide drug conjugates market. According to the National Cancer Institute, more than 1.8 million new cancer cases and 600,000 deaths from cancer will occur in the United States in 2020. Because of the launch of Melflufen and the rapid uptake of PDC drugs in cancer therapy, North America dominated the overall peptide drug con...